|
|||||
|
|
Authors’ reply to the letter to the editor by Olivier J.M. Guilbaud |
|
| Authors: | Cheng Zheng Jixian Wang Lihui Zhao |
| Institution: | 1. Novartis Pharmaceuticals Corp., One Health Plaza, , East Hanover, NJ, USA;2. Novartis Pharma AG, Postfach, , CH‐4002, Basel, Switzerland |
| Abstract: | |
| Keywords: | |